Q-omics provides the consensus-scored FAM90A12P profile across patient tissues and cancer cell-line models. FAM90A12P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FAM90A12P is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, FAM90A12P RNA expression shows 5,404 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight COAD, BRCA, and SKCM as cancer lineages where FAM90A12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM90A12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM90A12P survival associations across molecular data types. FAM90A12P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM90A12P RNA expression–survival associations across cancer types. High FAM90A12P expression shows unfavorable associations in COAD, LGG, UCS, BLCA and ESCA, but favorable associations in HNSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FAM90A12P RNA expression.
This table summarizes FAM90A12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM90A12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM90A12P shows lower tumor expression in BRCA and higher tumor expression in LUSC. The BRCA box plot shows higher FAM90A12P RNA expression in normal versus tumor tissue (log2 FC = −0.009, t-test p = .010).
This table shows molecular features associated with FAM90A12P in patient tissues and cancer cell lines. In patient samples, FAM90A12P shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
